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ABSTRACT: Rapid Evaporative Ionization Mass Spectrometry (REIMS) was used for the rapid mass spectrometric profiling of 
cancer cell lines. Spectral reproducibility was assessed for three different cell lines and extent of inter-class differences and intra-
class variance were found to allow the identification of these cell lines based on the REIMS data. Subsequently, the NCI60 cell line 
panel was subjected to REIMS analysis and the resulting dataset was investigated for its distinction of individual cell lines and 
different tissue types of origin. Information content of REIMS spectral profiles of cell lines were found to be similar to those 
obtained of mammalian tissues although pronounced differences in relative lipid intensity were observed. Ultimately, REIMS was 
shown to detect changes in lipid content of cell lines due to Mycoplasma infection. The data show that REIMS is an attractive 
means to study cell lines involving minimal sample preparation and analysis times in the range of seconds.  
INTRODUCTION 
Rapid Evaporative Ionization Mass Spectrometry (REIMS) 
is an ambient mass spectrometric method, which was recently 
developed for intra-operative tissue identification.1,2 In case of 
REIMS analysis, biological samples are rapidly heated up via 
Joule-heating and the resulting aerosol is directly transferred 
into the mass spectrometer. It was found that electrosurgical 
tools such as monopolar diathermy that are used in many open 
surgeries or the bipolar forceps as commonly applied in brain 
surgery can serve as ion sources following the REI (rapid 
evaporation ionization) mechanism. A chemical fingerprint of 
the sample is recorded by the mass spectrometric analysis of 
the charged particles carried by the aerosol created during 
ionization. REIMS profiles mainly display complex 
phospholipid species originating from the cell membranes and 
were shown to be highly specific to the histological or 
histopathological type of the tissues.1 More recently, we 
further developed the REIMS methodology to characterize and 
identify microorganisms including bacteria and fungi with 
excellent accuracies on species-, genus- and Gram-level. 
REIMS profiles showed sufficient specificity to allow strain-
level differentiation of seven Escherichia coli strains with an 
overall 88% accuracy independent of culturing conditions or 
the age of colonies.3 
This study on microorganisms and earlier studies on 
mammalian tissues revealed that the information content of the 
REIMS spectral profiles is not limited to species-level 
identification and tissue morphologies but contains additional 
information on the phenotype of the organism examined.1,3 
REIMS can therefore serve as a lipidomics-based shotgun 
phenotyping technique, however, the general sensitivity and 
specificity of the method to certain changes (as changes in 
protein expression patterns) in a biological system still need to 
be assessed.  
The traditional technique of choice for lipidomic profiling is 
liquid chromatography-mass spectrometry (LC-MS). 
However, even using state-of-the-art ultra-high performance 
liquid chromatography mass spectrometry (UPLC-MS), 
overall run-time per sample is still in the range of 10-20 
minutes and the analysis requires extensive sample preparation 
(homogenization, extraction, etc.). Several mass spectrometric 
profiling methodologies have been developed in the recent 
past and the field has gained additional momentum with the 
introduction of ambient mass spectrometry in 2004.4,5 Ambient 
mass spectrometric methods such as the most widely used 
Desorption Electrospray Ionization Mass Spectrometry (DESI-
MS), offer the capabilities to analyze samples in their native 
state, without any significant sample preparation steps.6 These 
ambient profiling technologies have recently been deployed in 
cancer studies to characterize the lipid composition of breast 
cancer compared to normal breast tissue7, the identification of 
cancer metastasis within lymph nodes8, colorectal cancer 
compared to normal mucosa9, and brain cancer10 among 
others. While these studies provided excellent basis for the 
development of novel diagnostic approaches, the molecular 
background of the distinction between different histological 
classes remains unclear, due to the limited coverage of tissue 
metabolome/lipidome/proteome and lack of functional tests 
(e.g. gene silencing) in case of human samples. A 
complementary approach for studying the molecular 
background of histologically specific lipid profiles involves 
the use of cell lines, which solves problems regarding sample 
availability and standardization of sampling, lifts most of the 
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 ethical constraints and also allows functional testing including 
gene silencing or metabolic flux analysis.  
Cell lines are a popular means of studying various 
biochemical and disease processes in vitro. In case of cancer 
studies the cell lines provide a means to study cancer 
development and progression as well as the investigation of 
pathobiochemical processes as close to the human body as 
possible while still allowing free manipulation of experimental 
parameters. One of the most extensively characterized cell line 
collections is the NCI60 cell line panel which was compiled 
by the National Cancer Institute as part of the In Vitro Cell 
Line Screening Project.11 The panel comprises 60 human 
cancerous cell lines from nine different organs of origin, 
namely leukemia, melanoma, cancers of the lung, colon, brain, 
ovary, breast, prostate, and kidney. Data available for these 
cell lines includes drug sensitivity patterns for more than 
100,000 compounds and natural products, global protein and 
gene expression data and common mutations associated with 
cancer.11-14 However, the associated metabolomics and 
lipidomics data is comparatively sparse. Although many 
publications are available investigating the lipid composition 
of certain types of cell lines using both chromatography-
based15,16 and shotgun mass spectrometry methods,4,17-20 to our 
knowledge there is no work available characterizing the 
lipidome of the NCI60 cell line panel as a whole using a single 
set of conditions. This represents a striking gap in the cancer-
related biochemical data, as complex lipids are the main 
constituents of cell membranes and play important functional, 
structural, and metabolic roles by acting as signaling 
molecules or as precursors for secondary messengers. 
Furthermore, changes in the membrane lipid composition can 
regulate function and availability of intrinsic membrane 
proteins and affect cell signaling mechanisms. REIMS, as 
other ambient ionization technologies (or desorption ionization 
technologies in general), yields abundant phospholipid signals 
due to the good ionization efficiency of polar lipids and their 
high abundance in biological tissues.  
Using REIMS, the objective of the current study is to 
establish and characterize the methodological background for 
acquiring shotgun lipid profiling data of large cell line cohorts 
such as the NCI60 cell line panel. Such methodology will aid 
future fundamental studies aimed at the exploration of the 
molecular background of intra-operative REIMS-based tissue 
identification. 
MATERIALS AND METHODS 
Culturing of cell lines. The NCI60 cell panel was obtained 
from the DCTD Tumor Repository (National Cancer Institute, 
Frederick, MD, USA); HEK, HeLA and MES-SA cell lines 
were from the ATCC collection (Manassas, VA, USA). All 
cells were cultured in RPMI 1640 medium with the exception 
of HEK and HeLa cells in the Mycoplasma study which were 
cultured in Gibco DMEM medium (Invitrogen, Carlsbad, CA, 
USA). In all cases, media were supplemented with 10% (v/v) 
fetal bovine serum, 2mM glutamine, 100 units/mL penicillin, 
and 100mg/mL streptomycin (Invitrogen). Cells were 
incubated in 75cm2 tissue culture flasks under conditions of 
humidified 37°C, 5% carbon dioxide atmosphere. Cell lines 
were regularly screened for Mycoplasma contamination using 
the MycoAlertTM Mycoplasma Detection Kit (Lonza Group 
Ltd, Basel Switzerland).  
At 80-90% confluence, cells were rinsed with Phosphate 
Buffered Saline (PBS, pH: 7.2) and detached using 0.1% 
trypsin/EDTA for 10 minutes. While scraped cells can also be 
analyzed by REIMS (and were used for initial analyses) 
Trypsin digestion prior to cell pelleting has been used in other 
lipid profiling studies of cells21,22 and were used for larger 
arms of the study as they offer easier automation for cell 
harvesting.21,22 The trypsin was subsequently neutralized with 
excess culture medium. The cell suspensions were centrifuged 
at 250×g for five minutes. After centrifugation the cells were 
re-suspended and washed two times in 10mL PBS. A third 
wash was performed in an Eppendorf tube with only 1mL 
PBS. The cell pellets were frozen and stored at -80°C until 
further analysis. 
Mycoplasma infection and treatment. Mycoplasma-
infected HEK and HeLa cell lines were treated with 25µg/mL 
Plasmocin™ Mycoplasma Elimination Reagent (InvivoGen, 
San Diego, CA, USA) for 14 days.  
REIMS analysis. For REIMS analysis, two handheld 
electrodes in form of a forceps were used as the sampling 
probe (irrigated bipolar forceps, obtained from Erbe 
Elektromedizin, Tübingen, Germany). A Valleylab Force EZc 
power-controlled electrosurgical unit (Covidien, Dublin, 
Ireland) was used at 60 W power setting in bipolar mode as 
radiofrequency alternating current power supply (470 kHz, 
sinusoidal). An approximately 1.5 m long 1/8 inch outer 
diameter, 1/16 inch inner diameter PTFE tubing (Fluidflon 
PTFE tubing; LIQUID-scan GmbH Co. KG, Überlingen, 
Germany) was employed to connect the embedded fluid 
transfer line of the bipolar forceps with the inlet capillary of a 
Thermo Exactive instrument (Thermo Scientific GmbH, 
Bremen, Germany). The inherent vacuum system of the mass 
spectrometer was used for aspiration of the analyte-containing 
aerosol created during analysis. This setup is adapted from 
earlier studies on microorganisms3 and shown in Figure 1 
while instrumental settings are given in Table S-1.  
 
Figure 1. Experimental setup used in this study for REIMS 
analysis of cell lines. Generated aerosol is sampled via the 
aspiration port in the head of the sampling probe and transported 
directly to the mass spectrometer using polymer tubing. 
Mass spectrometric analysis of the cell line biomass was 
performed directly on the thawed cell pellet without further 
sample pre-processing steps. For each measurement, 0.1-
1.5mg of cell biomass was taken up between the tips of the 
forceps and the two electrodes were subsequently brought into 
close proximity (i.e. by pinching the biomass between the tips 
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 of the forceps); the RF power supply was triggered using a 
foot switch. The cell line biomass is rapidly heated up due to 
its non-zero impedance and an aerosol containing charged 
molecular species of the analytes is produced and transferred 
directly into the mass spectrometer. Multiple technical 
replicates were recorded for each cell line. Ionic species in the 
mass spectra were identified based on exact mass 
measurements (mass deviation <3ppm) and MS/MS 
fragmentation patterns. 
Data Analysis. Raw mass spectrometric files were 
converted into mzML format using the MSConvert tool (part 
of the ProteoWizard suite, version 3.0.4043) and subsequently 
imported as imzML format into MATLAB (Mathworks, 
Natick, MA; http://www.mathworks.co.uk/) for data pre-
processing.3,23,24 All REIMS spectra were linearly interpolated 
to a common sampling interval of 0.01 Da. Recursive 
segment-wise peak alignment was then used to remove small 
mass shifts in peak positions across spectral profiles.25 The 
aligned data were subjected to total ion count (TIC) data 
normalization and log-based transformation. Pattern 
recognition analysis and visualization were performed either 
in Matlab or in RStudio (Boston, MA, USA, see also www.r-
project.com).26 The mass range of m/z 150-1000 was used for 
data analysis in all studies. For self-identity experiments, the 
data set was filtered to keep a reduced set of m/z values: a m/z 
value was kept, if the difference between the available samples 
were significantly different at alpha=0.01 threshold level 
based on the Kruskal-Wallis test. For each cross-validation 
run, a principal component analysis (PCA) transformation of 
the training data set with pre-determined number of principal 
components (PCs) was calculated in R and prediction score 
was calculated for each test sample using the 3 nearest 
neighbor (3-NN) method. The training data in the 'spectral 
reproducibility set' was selected as follows: for each 
measurement day, a cell line with defined passage (p) and 
flask number (A/B) was kept as part of the training data (i. e. 
HeLa p4 A) if samples were available from at least two 
different biological replicates (i.e. A1-3). Such sets from each 
of the three cell lines were combined randomly to produce 
balanced training data where each cell line is represented by 
similar number of samples. All of the remaining samples 
constituted the test set. In the ‘NCI60 data set’, where 
applicable, one of the biological replicates was omitted while 
the remaining data constituted the training set. 
Safety Considerations. To avoid any negative health 
impact originating from aerosolized cancer cells, the analysis 
site was enclosed into a Class II safety level glove box 
compartment equipped with UV light source and HEPA 
filters. 
RESULTS AND DISCUSSION 
Robustness of REIMS spectral profiles 
REIMS analysis has been applied to different types of 
biological samples and showed good spectral pattern 
reproducibility in case of human tissues and microorganisms 
including both bacteria and fungi.1,3 To test the general 
hypothesis that REIMS spectral patterns are reproducible and 
sufficiently specific to differentiate between different human 
cancer cell lines, three different cell lines (HeLa – cervical 
adenocarcinoma, MES-SA – uterine sarcoma, and SNB-19 – 
glioblastoma) were analyzed in an experiment designed to test 
spectral reproducibility. The experimental scheme depicted in 
Figure S-1 accounts for variance introduced by different 
culture batches or the passage number and for analytical 
variance introduced by the multiple measurements. Replicates 
were randomly analyzed over three analysis days in order to 
assess the analytical variance and robustness of a REIMS-
based lipid profiling method. In addition, the influence of one 
freeze-thaw cycle on spectral variance was investigated and 
was found to be insignificant. Detailed sampling schedules can 
be found in Table S-2. 
 
Figure 2. A) Representative mass spectral profiles between m/z 
600-900 as obtained for HeLa, MES-SA, and SNB cell line 
pellets. B) 3-dimensional PCA plot of averaged REIMS data 
collected from several independent cultures of HeLa, MES-SA 
and SNB-19 cells over the spectral mass range of m/z 600-900.  
Raw REIMS profiles of all three cell lines show a high 
degree of similarity (Figure 2A, see Figure S-3 for mass range 
of m/z 150-1000). Earlier studies demonstrated that REIMS is 
suitable to generate phospholipid profiles of various biological 
materials such as animal tissues,2,27,28 human ex-vivo tissue 
samples of healthy and cancerous origin,1,29 as well as 
microorganisms.3,30 As analysis is performed in negative ion 
mode, the spectral content is similar to that described in those 
earlier studies featuring predominantly glycerophospholipid-
type membrane lipids such as phosphatidylethanolamines 
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 (PEs), phosphatidylinositols (PIs), phosphatidylglycerols 
(PGs), phosphatidic acids (PAs) and phosphatidylserines (PSs) 
as well as other complex lipids including ceramides and 
glycosylated ceramide species. All observed ions displayed a 
single negative charge, the vast majority by forming the quasi-
molecular [M-H]- ion. In addition, [M-NH3-H]
- and [M-
NH3+Cl]
- were observed in case of PEs. Sphingolipid species 
were detected as [M+Cl]- ions. A list of spectral features 
above a relative abundance of 2.5% with molecular 
assignments can be found in Table S-5. All identified spectral 
features were found to be lipids. The vast majority of lipid 
species detected using REIMS could also be detected in LC-
MS measurements of the same cell lines (see Table S-5). For 
details about LC-MS sample preparation and instrument 
parameters the reader is referred to the Supplementary 
Information (Table S-3 and S-4). 
For clinically oriented applications, REIMS spectral profiles 
were largely analyzed using supervised multivariate statistical 
methods such as linear discriminant analysis (LDA) to explore 
the differentiation of various tissue types or healthy and 
diseased tissues.1,27 In this study, we intentionally restricted 
ourselves to exploratory unsupervised analysis methods to 
assess whether REIMS profiles would reproducibly cluster 
into different groups corresponding to cell line identities. 
Table 1. Cross-validation results for SNB-19, HeLa and 
MES-SA cell lines based on a PCA model comprising the 
first 4 principal components and using 3 nearest neighbor 
as classifier. 
Kept in test set 
Predicted 
Accuracy 
HeLa MES-SA SNB-19 
HeLa p6 A day2 
(9 samples) 
63 - - 100% 
MES-SA p8 A day1  
(9 samples) 
2 57 - 97% 
SNB-19 p4 A day1  
(9 samples) 
- - 54 100% 
HeLa p4 B day2  
(9 samples) 
62 1 - 98% 
MES-SA p10 B day1  
(9 samples) 
17 42 - 71% 
SNB-19 p4 B day2  
(7 samples) 
- - 56 100% 
HeLa p4 A day1  
(9 samples) 
49 14 - 78% 
MES-SA p10 A day3  
(12 samples) 
- 56 - 100% 
SNB-19 p6 A day2  
(7 samples) 
- 1 55 98% 
 
PCA of the REIMS profiles defined three clusters (Figure 
2B), corresponding to the three cell lines. SNB-19 cells are 
clearly differentiated from HeLa and MES-SA cells along the 
first principal component. The second and the third principal 
component are required to fully separate HeLa and MES-SA 
cell lines from each other. A slight separation along the second 
principal component due to passage numbers was observed for 
HeLa and SNB-19, however, analytical and biological 
variances were found to be small compared to the inherent 
spectral differences of the cell lines. These results suggest that 
although there is an expected biological and analytical 
variance, the REIMS spectral profiles obtained from cell line 
pellets show sufficient reproducibility and specificity to 
characterize and distinguish human cancer cell lines. 
Cross-validations were performed based on a PCA model 
created of training sets as described in Materials and Methods. 
Following this procedure, three different training sets were 
generated and subjected to PCA analysis. These training sets 
comprised between 25-28 sampling points, which represent 
<15% of the overall data points (n=203). The composition of 
the training sets and corresponding cross-validation results are 
shown in Table 1. Consistently, the cross-validation results 
show ≥98% correct classification for SNB-19 samples, with 
only a single misclassification observed in case of the third 
training set, which was tentatively associated with the unequal 
sample size for MES-SA (n=12) and SNB-19 (n=7). Unequal 
sample size is known to lead to a bias in PCA calculations 
towards the larger sample subset, which explains the 
misclassification of SNB-19 cells as MES-SA. While the first 
test set proved very robust for the classification of all three 
cell lines, the second and third test sets lead to occasional 
misclassifications between MES-SA and HeLa cells, 
respectively. This suggests a more close spectral relationship 
between HeLa (cervical origin) and MES-SA (uterine origin) 
compared to the SNB-19 cells (CNS origin) as was also 
observed in the PCA analysis as described above.  
Significantly different m/z values were derived for all three 
cell lines using ANOVA in a one-against-all approach. Both 
significantly increased and significantly decreased m/z values 
can be found in Table S-6. Similar trends for these 
significantly changed species are shown for the same three cell 
lines using LC-MS measurements (see Figure S-2 for box 
plots derived from either methodology).  
REIMS profile of the NCI60 cell line panel 
Following the confirmation that REIMS spectral patterns 
are able to distinguish between three cancer cell lines, we set 
out to profile the entire NCI60 panel, consisting of 60 human 
different cancer cell lines. Based on amount of available 
biomass after culture, we recorded 4 to 15 individual 
measurement points for each cell line, and included eight 
biological replicates (see Table S-7 for detailed sample set). 
Hierarchical cluster analysis (HCA; Figure 3) and principal 
component analysis (Figure S-4) of the filtered spectral 
averages were performed. The spectral content of the different 
cell lines was compared and no mass spectrometric signals 
were unique for a single cell line only. Rather, changes in lipid 
content were of a relative nature and clustering behavior of 
cell lines was due to pattern-level changes rather than changes 
in the relative intensity of a few species. Biological replicates 
showed the expected level of similarity as indicated by the 
cluster analysis (Figure 3) showing close clustering in the 
HCA dendrogram. This is true for all cell lines except 
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Figure 3. Cluster dendrogram of the NCI60 panel including independently cultured replicates (highlighted by asterisks) or biologically 
related cell lines (blue arrows). REIMS lipidomic profiles distinguish cell lines of the NCI60 panel consisting of ovarian (OV, green), renal 
(RE, brown), melanoma (ME, light blue), central nervous system (CNS, light green), breast (BR, black), lung (LC, blue), colon (CO, red), 
leukemia (LE, purple) and prostate (PR, yellow) origin. Distance was calculated using Pearson correlation and agglomeration via the Ward 
metric. 
IGROV-1 and SF-268. In case of IGROV-1, a comparably 
small number of 3 and 5 REIMS spectra were available for 
each respective replicate, which was tentatively associated 
with the incorrect classification. The spectral difference 
observed in the case of SF-268 raises the possibility of strong 
biological variance or a potentially compromised biological 
replicate. Similar results were obtained for cross-validation 
results performed on the PCA model (see Table S-8 for 
identification accuracies based on PCA model shown in Figure 
S-4) which reveal partial misclassification for IGROV-1 and 
no correct results for SF-268. 
Gene expression profiling revealed that the MDA-MB-435 
cells more closely resembled melanoma cell lines than the 
other breast tumor lines.31 Consistent with gene expression,32 
SNP33 and karyotype analyses,34 the REIMS profiles also 
indicate that MDA-MB-435 and M14 are closely related 
(Figure 3, blue arrow, right). Karyotyping has also found that 
NCI-ADR-RES is in fact a drug-resistant derivative of 
OVCAR-8.35 As shown in Figure 3, these cell lines (indicated 
by blue arrow, left) also show close similarity based on their 
REIMS profiles. Taken together, these results confirm that 
REIMS profiles are strongly associated with the biological 
identity of cancer cell lines. Gene and protein expression 
patterns of the NCI-60 panel were found to correlate with 
tissue type of origin to some extent,12,32 whereas metabolic 
signatures did not differentiate well between tissue origins.14 
Clustering of the cell lines based on their REIMS lipid profile 
showed extensive heterogeneity within most tissue types, 
except for melanoma samples (Figure 3, light blue colored cell 
lines).  
In previous studies, the REIMS spectral profile of ex-vivo 
human tissue specimens was shown to be highly specific for 
the histological/anatomical tissue type.1 REIMS profiles of the 
NCI60 panel were subsequently compared to bulk cancer 
samples of ovarian and colon adenocarcinomas analyzed using 
the same experimental setup. A PCA plot of the resulting 
dataset is shown in Figure 4A and reveals clear differences 
between cell lines and bulk tissue specimens along the first 
principal component suggesting strong differences among 
their membrane lipid composition. A tentative separation 
according to tissue type of origin can be observed for both cell 
lines and tissue specimens, although more pronounced in the 
latter. Only a small number of tissue specimens (n=4) were 
available in case of ovarian tumors, but based on previous 
studies a significant increase in separation power can be 
expected for larger sample sets.1 Nevertheless, the direction of 
separation is similar in both cases, suggesting similar 
lipidomic differences.  
Representative spectral profiles in the mass range of 600-
900Da of both ovarian and colon cancer tissue and cell line 
samples are shown in Figure 4B (see Figure S-5 for REIMS 
spectral profiles ranging from 150-1000Da). Significantly 
different m/z values between bulk tissues and cell lines of the 
same tissue of origin were derived using ANOVA and are 
shown in Table S-9. Box plots for representative m/z species 
are shown in Figure S-6. Bulk tissues display larger amounts 
of long-chain phosphatidylinositols such as PI(38:4) at m/z 
885.55. Similar trends were observed in case of certain 
phosphatidylethanolamines, for instance the peaks detected in 
the mass range of m/z 790-794 corresponding to PE(40:6)-
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6
PE(40:4) species or those occurring at m/z 766.54 and 768.55 
corresponding to PE(38:4) and PE(38:3), respectively. On the 
other hand, predominantly shorter chain PEs and PAs with 30-
36 cumulative carbon chain lengths were found to be more 
abundant in cell lines. We speculate that the characteristic 
differences in lipid composition are due to the uniform lipid 
content of the culturing medium, which does not recapitulate 
the complex lipid source of real tumors that rely on dietary 
and liver-synthesized lipids as well as de-novo lipid synthesis.  
 
Figure 4. A) 2-dimensional PCA plot of REIMS data collected 
from the NCI60 cells (squares) and cancer tissue samples 
(circles). The tissue of origin is indicated by red (colon) and blue 
(ovarian) colors. B) Comparison of spectral profiles for bulk 
tissue samples and cell lines of the corresponding tissue type of 
origin for i) ovarian cancer and ii) OVCAR-3 cell line, iii) 
colorectal cancer and iv) HCT-15 cell line. 
Analysis of Mycoplasma-infected cell lines 
Mycoplasma contamination is a major problem in both basic 
and applied research. Infection with Mycoplasma alters many 
physiological processes and often confounds experimental 
results. PlasmocinTM (InvivoGen, San Diego, CA, USA) is a 
commercially available antibiotic treatment that is frequently 
used to eradicate Mycoplasma infection in cell cultures.36 
REIMS profiles of Mycoplasma-free, Mycoplasma-infected 
and PlasmocinTM-treated HEK and HeLa cell lines were 
recorded. The dataset was pre-processed as described for the 
NCI60 panel. Our aim was to identify m/z values showing 
significantly different intensity between Mycoplasma-positive 
and -negative samples. Adjusted p-values were obtained using 
the adaptive Benjamini–Hochberg (BH) procedure to correct 
for multiple testing.37 As shown in Figure 5A, 23 and 386 
binned m/z signals were significantly higher in Mycoplasma-
infected HEK and HeLa cells, respectively. The higher 
number of significantly increased peaks found for HeLa cells 
may be explained with a higher number of sampling points 
(contributing to higher power in significance testing) or may 
reflect the increased reactivity of HeLa cells to Mycoplasma 
infection. Interestingly, we found only one signal showing 
reduced intensity in Mycoplasma-infected cell lines. Table S-
10 lists the tentative annotation of the 18 m/z signals that were 
found to be significantly increased across all Mycoplasma-
infected cells. 
 
 
Figure 5. A) Number of significantly higher m/z signals in 
Mycoplasma-infected versus Mycoplasma-free samples in HEK 
and HeLa cell lines. B) Mycplasma-infected (+) and Mycoplasma-
free (-) HEK (rectangle) and HeLa (triangle) cells that were either 
treated (t) or untreated (u). Samples are shown as a function of 
PC1 and PC2 of PCA transformed data points in the space of the 
18 overlapping m/z signals. 
Page 6 of 9
ACS Paragon Plus Environment
Analytical Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
  
7
As an example, changes in the intensity of m/z 819.52 
(identified as PG(40:7) based on exact mass measurements) 
are shown in Mycoplasma-free, Mycoplasma-infected and 
PlasmocinTM-treated HEK and HeLa cells (Figure S-7). This 
m/z value, along with the signal corresponding to its isotope, 
was found to be increased in Mycoplasma-infected HeLA and 
HEK cells, whereas the intensity returned to pre-infection 
levels upon successful PlasmocinTM treatment. Similar results 
were obtained for the other m/z signals listed in Table S-10.  
In the 18 dimensional space of these m/z signals, 
Mycoplasma-infected and Mycoplasma-free HEK and HeLa 
samples were analyzed by PCA (Figure 5B). The first 
principal component (PC1) reveals differences between the 
two different cell lines while the second PC separates 
Mycoplasma-free and Mycoplasma-infected samples. The 
significantly increased signals correspond to 
phosphoglycerolipids that are however also present in healthy 
cell lines, suggesting that the changes delineated by the 
statistical analysis are not due to the presence of bacterial 
lipids. Rather, we speculate that the peaks showing increased 
intensity reflect changes that are associated with the reversible 
response of the host cells’ lipid metabolism to Mycoplasma 
infection.38 Our results indicate that REIMS analysis can 
identify spectral changes evoked by Mycoplasma infection. 
Future studies will delineate the complex effect of 
Mycoplasma infection on the lipidomic profiles of cell lines 
and reveal the applicability of the REIMS technology in the 
rapid and reliable detection of Mycoplasma infection.  
CONCLUSION 
This proof-of-principle study demonstrates the applicability 
of a REIMS-based shotgun lipidomic characterization 
approach for human cancerous cell lines. Individual cancer 
cell lines were found to exhibit reproducible and cell line-
specific spectral profiles while spectra could be acquired in 
less than five seconds. REIMS analysis does not only allow 
rapid identification of cell lines based on their spectral 
fingerprint, but opens the way to the detailed characterization 
of membrane lipid composition in different cancer phenotypes. 
The correlation between REIMS spectral data and gene and 
protein expression data can be assessed using publicly 
available resources such as the CellMiner database 39 which 
will allow to assess the sensitivity of the REIMS spectral 
method for tumor phenotypic characterization in detail. In 
addition, this technique offers a unique possibility to 
investigate gene knock-out models for changes in lipid 
metabolism or the effects of feeding experiments with stable 
isotope-labeled nutrient sources.  
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